Vincristine Sulfate

Splenic Marginal Zone Lymphoma

SWOG Cancer Research NetworkSmall moleculePhase 3Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 62/ 100
Competitive Position: 81/ 100

Competitive context

31 Active assets in the Splenic Marginal Zone Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Etoposide Fred Hutchinson Cancer Center	Phase 2	BB
Zanubrutinib SWOG Cancer Research Network	Phase 3	BB
Cediranib National Cancer Institute (NCI)	Phase 2	BB
Dexasone Izidore Lossos, MD	Phase 2	BB
Cyclosporin A National Cancer Institute (NCI)	Phase 2	BB

View all 50 →

Same molecule, other indications

Vincristine Sulfate is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant

A

Indicative · Phase 3

81 / 100

diffuse large B-cell lymphomaActive

A

Indicative · Phase 2/3

80 / 100

childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.